White House Pulls Heidi Overton's FDA Nomination Hours Before Senate Vote
The White House withdrew Heidi Overton's FDA commissioner nomination hours before a Senate vote. The agency has lacked a permanent leader since Marty Makary departed in May, with Kyle Diamantas serving as interim chief.
TAG T-7561 · 499 words on the filing

Summary of findings
- White House pulled Heidi Overton's FDA nomination hours before a scheduled Senate vote, Axios reported Tuesday evening.
- The FDA has had no permanent commissioner since Marty Makary left in May; Kyle Diamantas serves as interim leader.
- HELP Committee vote was set for Nov. 18 after Overton's contentious September hearing.
- Citi analysts called the withdrawal a 'modest sentiment negative' extending leadership uncertainty for sponsors.
- Republicans are discussing Sen. Roger Marshall of Kansas as a potential replacement, Semafor reported.
The White House has pulled Heidi Overton's nomination to lead the FDA just hours before the Senate was scheduled to vote on her confirmation, Axios first reported Tuesday evening.
The withdrawal caps a nomination that never found firm footing. Overton, M.D., Ph.D., appeared before the Senate Health, Education, Labor and Pensions (HELP) Committee in September, where senators pressed her on vaccines, abortion, flavored vapes and whether President Donald Trump is capable of being wrong on medical matters.
What sank the nomination?
During the hearing, Overton conceded multiple times that FDA-approved vaccines and the abortion pill mifepristone are safe and effective. But she stopped short of admitting Trump has been wrong when dispensing medical information that runs counter to scientific evidence.
That hedge cost her on both sides of the aisle. Support looked thin heading into a planned HELP Committee vote on Nov. 18, with Republicans as well as Democrats voicing doubts. Committee chair Sen. Bill Cassidy, Republican of Louisiana, had raised questions about the nomination alongside other GOP senators.
Sen. Ed Markey, the Massachusetts Democrat, told Fierce ahead of the vote that he would "vote against her nomination, and I urge my colleagues to do the same."
"The FDA needs a leader who will stand up for science and for our kids' safety, not one who stood by while both were undermined," Markey said.
Outside groups piled on. Robert Steinbrook, M.D., health research group director for Public Citizen, urged the HELP Committee to reject Overton on Tuesday: "The FDA needs a strong commissioner who stands for science and the integrity of the agency. Overton is the wrong choice for FDA Commissioner and has done nothing to dispel the well-founded reasons to oppose her candidacy."
Who's next in line?
With Overton out, Republicans are already discussing Sen. Roger Marshall, the Kansas Republican, as a potential replacement, Semafor reported Tuesday.
The White House only turned to Overton in August, after the agency had spent three months without a permanent leader. Former FDA commissioner Marty Makary, M.D., departed in May. Kyle Diamantas, who came up through the agency's food regulation division, has been running the FDA in an interim capacity since.
What does this mean for sponsors?
For biopharma, the practical read is limited but negative. Citi analysts said the withdrawal "extends uncertainty around permanent agency leadership" and called it "a modest sentiment negative, but not a material near-term change to the regulatory environment facing most drug and biologics sponsors."
In other words: no immediate shift in review dynamics for drug and biologics applicants. The damage is cumulative — an agency already shaken by months of upheaval now faces a longer stretch without a Senate-confirmed commissioner, and a replacement process that starts over from the vetting stage.
Whoever emerges — Marshall or another candidate — will need to clear the same HELP Committee that just rejected two nominees' worth of consensus on vaccines, mifepristone and the political independence of the agency's scientific calls.
via FDA industry wire (Google News) (Source)
More from Marcus Bennett
Show full bio
News editor covering regulation, policy and their impact on global pharmaceutical industry at PharmInsider.
10 articles
Linked filings
- E-5590
- T-7549
- T-7183
- E-4696
- T-2239